Tarsus Pharmaceuticals, Inc. (TARS): Total Assets
$562.16M
As of 2025-12-31
$611.14M
As of 2026-06-30
+35.1%
3-year compound annual growth
+26.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $562.16M | +49.1% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $376.99M | +42.0% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $265.49M | +16.5% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $227.86M | +27.4% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $178.91M | +4.0% | 2023-03-17, Balance as of period end |
| 2020-12-31 | $171.97M | +194.9% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $58.32M | n/a | 2021-03-31, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $562.16M | +49.1% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $1.07B | +5.7% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $624.24M | +27.7% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $1.33B | +26.3% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $641.86M | +4.5% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $512.74M | -4.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $487.97M | +12.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $913.17M | +0.3% |
Compare TARS, IMCR, ADMA, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗